美国食品和药物管理局批准新药WAYRILZ用于治疗成年人的慢性免疫血栓缺血症. FDA approves new drug WAYRILZ to treat chronic immune thrombocytopenia in adults.

林业发展局批准了WAWRILZ(rilzabrutinib),这是第一个BTK抑制剂,用于治疗那些对以前的治疗没有反应的患有慢性免疫性血栓球球菌(ITP)的成人。 The FDA has approved WAYRILZ (rilzabrutinib), the first BTK inhibitor for treating adults with chronic immune thrombocytopenia (ITP) who have not responded to previous treatments. ITP影响约67 000名美国病人,导致小盘数低,出血风险增加。 ITP affects about 67,000 U.S. patients, causing low platelet counts and increased bleeding risk. 临床试验显示,WAWRILZ的血盘计数显著增加,生活质量提高,常见副作用包括腹泻、恶心和头痛。 Clinical trials showed WAYRILZ significantly increased platelet counts and improved quality of life, with common side effects including diarrhea, nausea, and headache.